Compare NGVT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | VCEL |
|---|---|---|
| Founded | 1964 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | NGVT | VCEL |
|---|---|---|
| Price | $65.64 | $37.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.00 | $57.50 |
| AVG Volume (30 Days) | 290.6K | ★ 597.0K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,382,100,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | $2.28 | $18.55 |
| P/E Ratio | ★ N/A | $150.23 |
| Revenue Growth | 5.63 | ★ 14.05 |
| 52 Week Low | $28.49 | $29.24 |
| 52 Week High | $66.59 | $63.00 |
| Indicator | NGVT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.20 | 50.35 |
| Support Level | $58.87 | $36.12 |
| Resistance Level | $63.03 | $41.65 |
| Average True Range (ATR) | 1.52 | 1.59 |
| MACD | 0.38 | 0.09 |
| Stochastic Oscillator | 88.86 | 38.92 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.